These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 32056516)

  • 1. Clinical and Translational Challenges in Thyroid Cancer.
    Hernando J; Ros J; Arroyo A; Capdevila J
    Curr Med Chem; 2020; 27(29):4806-4822. PubMed ID: 32056516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel targeted therapies and immunotherapy for advanced thyroid cancers.
    Naoum GE; Morkos M; Kim B; Arafat W
    Mol Cancer; 2018 Feb; 17(1):51. PubMed ID: 29455653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medullary thyroid carcinoma beyond surgery: advances, challenges, and perspectives.
    Ceolin L; Duval MADS; Benini AF; Ferreira CV; Maia AL
    Endocr Relat Cancer; 2019 Aug; 26(9):R499-R518. PubMed ID: 31252403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diversity of mutations in the RET proto-oncogene and its oncogenic mechanism in medullary thyroid cancer.
    Hedayati M; Zarif Yeganeh M; Sheikholeslami S; Afsari F
    Crit Rev Clin Lab Sci; 2016 Aug; 53(4):217-27. PubMed ID: 26678667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular Targeted Therapies of Aggressive Thyroid Cancer.
    Ferrari SM; Fallahi P; Politti U; Materazzi G; Baldini E; Ulisse S; Miccoli P; Antonelli A
    Front Endocrinol (Lausanne); 2015; 6():176. PubMed ID: 26635725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel Targeted Therapies for Metastatic Thyroid Cancer-A Comprehensive Review.
    Al-Jundi M; Thakur S; Gubbi S; Klubo-Gwiezdzinska J
    Cancers (Basel); 2020 Jul; 12(8):. PubMed ID: 32751138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular events in follicular thyroid tumors.
    Kroll TG
    Cancer Treat Res; 2004; 122():85-105. PubMed ID: 16209039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perspectives on the Treatment of Advanced Thyroid Cancer: Approved Therapies, Resistance Mechanisms, and Future Directions.
    Porter A; Wong DJ
    Front Oncol; 2020; 10():592202. PubMed ID: 33569345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of advanced thyroid cancer with targeted therapies: ten years of experience.
    Viola D; Valerio L; Molinaro E; Agate L; Bottici V; Biagini A; Lorusso L; Cappagli V; Pieruzzi L; Giani C; Sabini E; Passannati P; Puleo L; Matrone A; Pontillo-Contillo B; Battaglia V; Mazzeo S; Vitti P; Elisei R
    Endocr Relat Cancer; 2016 Apr; 23(4):R185-205. PubMed ID: 27207700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRAF(V600E) Mutation, RET/PTC1 and PAX8-PPAR Gamma Rearrangements in Follicular Epithelium Derived Thyroid Lesions - Institutional Experience and Literature Review.
    Şahpaz A; Önal B; Yeşilyurt A; Han Ü; Delibaşı T
    Balkan Med J; 2015 Apr; 32(2):156-66. PubMed ID: 26167339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lenvatinib: Role in thyroid cancer and other solid tumors.
    Cabanillas ME; Habra MA
    Cancer Treat Rev; 2016 Jan; 42():47-55. PubMed ID: 26678514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An update on molecular biology of thyroid cancers.
    Omur O; Baran Y
    Crit Rev Oncol Hematol; 2014 Jun; 90(3):233-52. PubMed ID: 24405857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.
    Ito Y; Onoda N; Ito KI; Sugitani I; Takahashi S; Yamaguchi I; Kabu K; Tsukada K
    Thyroid; 2017 Sep; 27(9):1142-1148. PubMed ID: 28635560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of hereditary medullary thyroid carcinoma.
    Pappa T; Alevizaki M
    Endocrine; 2016 Jul; 53(1):7-17. PubMed ID: 26839093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New therapeutic advances in the management of progressive thyroid cancer.
    Woyach JA; Shah MH
    Endocr Relat Cancer; 2009 Sep; 16(3):715-31. PubMed ID: 19218279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Classical point mutations of RET, BRAF and RAS oncogenes are not shared in papillary and medullary thyroid cancer occurring simultaneously in the same gland.
    Ciampi R; Romei C; Pieruzzi L; Tacito A; Molinaro E; Agate L; Bottici V; Casella F; Ugolini C; Materazzi G; Basolo F; Elisei R
    J Endocrinol Invest; 2017 Jan; 40(1):55-62. PubMed ID: 27535135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differentiated thyroid cancers: a comprehensive review of novel targeted therapies.
    Kojic KL; Kojic SL; Wiseman SM
    Expert Rev Anticancer Ther; 2012 Mar; 12(3):345-57. PubMed ID: 22369326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New molecular targeted therapies in thyroid cancer.
    Milano A; Chiofalo MG; Basile M; Salzano de Luna A; Pezzullo L; Caponigro F
    Anticancer Drugs; 2006 Sep; 17(8):869-79. PubMed ID: 16940797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolving molecularly targeted therapies for advanced-stage thyroid cancers.
    Bible KC; Ryder M
    Nat Rev Clin Oncol; 2016 Jul; 13(7):403-16. PubMed ID: 26925962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medullary thyroid carcinoma: a review on ethical considerations in treatment of children.
    Nozhat Z; Hedayati M
    J Pediatr Endocrinol Metab; 2016 Jun; 29(6):633-9. PubMed ID: 26974132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.